Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Vor Bio Phase 3 Study In China Shows Telitacicept Achieved Primary Endpoint Of Reducing Proteinuria In IgA Nephropathy With Significant Kidney Function Stabilization And Favorable Safety Profile

Author: Benzinga Newsdesk | November 10, 2025 04:02am

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile
Telitacicept demonstrated a 55% reduction in 24-hour urine protein-to-creatinine ratio (24h-UPCR) at 39 weeks compared with placebo; statistically significant benefits also achieved across all key secondary endpoints
Data presented as late-breaking oral presentation at American Society of Nephrology's Kidney Week 2025

Posted In: VOR